Revizinone

Revizinone

SCHEMBL29557974

CN(C(=O)CO/N=C(\c1ccccc1)c1ccc2c(c1)CN1CC(=O)NC1=N2)C1CCCCC1

nearest known ligand 0.68

Full drug profile on Sugi Atlas →

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
PDE3B Q13370 18/20 0.68
PDE3A Q14432 18/20 0.68
PDE4A P27815 3/20 0.60
PDE4B Q07343 3/20 0.60
PDE4C Q08493 3/20 0.60
PDE4D Q08499 3/20 0.60
P2RY12 Q9H244 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Revizinone SCHEMBL9584593 1.00 PDE3B (0.68) PDE3BPDE3APDE4APDE4BPDE4C
Revizinone SCHEMBL7297062 1.00 PDE3B (0.68) PDE3BPDE3APDE4APDE4BPDE4C
Revizinone SCHEMBL7289525 1.00 PDE3B (0.68) PDE3BPDE3APDE4APDE4BPDE4C
SCHEMBL9584441 0.91 PDE3B (0.70) PDE3BPDE3APDE4APDE4BPDE4C
SCHEMBL9584347 0.91 PDE3B (0.72) PDE3BPDE3APDE4APDE4BPDE4C
SCHEMBL9584335 0.91 PDE3B (0.72) PDE3BPDE3APDE4APDE4BPDE4C
SCHEMBL9583358 0.91 PDE3B (0.70) PDE3BPDE3APDE4APDE4BPDE4C
SCHEMBL9583372 0.91 PDE3B (0.70) PDE3BPDE3APDE4APDE4BPDE4C
Water SCHEMBL9583851 0.90 PDE3B (0.71) PDE3BPDE3APDE4APDE4BPDE4C
Water SCHEMBL9583863 0.90 PDE3B (0.71) PDE3BPDE3APDE4APDE4BPDE4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220347170-A1 Method of Reducing Brow Ache LENZ THERAPEUTICS OPERATIONS, INC. 2022-11-03 US disclosed
WO-2022232205-A1 A METHOD OF REDUCING BROW ACHE LENZ THERAPEUTICS, INC. (US) 2022-11-03 WO disclosed
CN-114340631-A Combination for reducing serum phosphate in a patient 阿德利克斯股份有限公司 2022-04-12 CN disclosed